Premium
Bisphosphonate nephropathy: A case series and review of the literature
Author(s) -
Roij van Zuijdewijn Camiel,
Dorp Wim,
Florquin Sandrine,
Roelofs Joris,
Verburgh Kees
Publication year - 2021
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.14780
Subject(s) - bisphosphonate , medicine , renal function , nephropathy , osteoporosis , urology , osteonecrosis of the jaw , bone density conservation agents , endocrinology , bone density , diabetes mellitus
From rat studies, human case reports and cohort studies, bisphosphonates seem to impair renal function. However, when critically reviewing the literature, zoledronate and pamidronate are more frequently involved in renal deterioration than other bisphosphonates. When bisphosphonate nephropathy occurs, zoledronate more frequently induces tubular toxicity whereas pamidronate typically induces focal segmental glomerulosclerosis. Thus, although bisphosphonates are highly effective in preventing complications for patients with osseous metastases and are highly effective in preventing fractures for patients with osteoporosis, renal function should be monitored closely after initiation of these drugs.